• 1
    Khan KS, Chien PF. Evaluation of a clinical test. I: assessment of reliability. BJOG 2001;108:5627.
  • 2
    Chien PF, Khan KS. Evaluation of a clinical test. II: assessment of validity. BJOG 2001;108:56872.
  • 3
    Coomarasamy A, Braunholtz D, Song F, Taylor R, Khan KS. Individualising use of aspirin to prevent pre-eclampsia: a framework for clinical decision making. BJOG 2003;110:8828.
  • 4
    Bossuyt PM, Lijmer JG, Mol BW. Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet 2000;356:18447.
  • 5
    McParland P, Pearce JM, Chamberlain GV. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet 1990;335:15525.
  • 6
    Morris JM, Fay RA, Ellwood DA, Cook CM, Devonald KJ. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol 1996;87:748.
  • 7
    Bower SJ, Harrington KF, Schuchter K, McGirr C, Campbell S. Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol 1996;103:6259.
  • 8
    Zimmermann P, Eirio V, Koskinen J, Niemi K, Nyman R, Kujansuu E, et al. Effect of low-dose aspirin treatment on vascular resistance in the uterine, uteroplacentan, renal and umbilical arteries – a prospective longitudinal study on a high risk population with persistent notch in the uterine arteries. Eur J Ultrasound 1997;5:1730.
  • 9
    Harrington K, Kurdi W, Aquilina J, England P, Campbell S. A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. Ultrasound Obstet Gynecol 2000;15:138.
  • 10
    Vainio M, Kujansuu E, Iso-Mustajarvi M, Maenpaa J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002;109:1617.
  • 11
    Yu CK, Papageorghiou AT, Parra M, Palma DR, Nicolaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet Gynecol 2003;22:2339.
  • 12
    Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14–16 weeks pregnancy: randomized controlled clinical trial. Croat Med J 2005;46:82631.
  • 13
    Goffinet F, Aboulker D, Paris-Llado J, Bucourt M, Uzan M, Papiernik E, et al. Screening with a uterine Doppler in low risk pregnant women followed by low dose aspirin in women with abnormal results: a multicenter randomised controlled trial. BJOG 2001;108:5108.
  • 14
    Subtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G, et al. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Regional Aspirine Mere- Enfant study (Part 2). BJOG 2003;110:48591.
  • 15
    Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000;107:196208.
  • 16
    Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:136791.
  • 17
    Cnossen JS, Morris RK, ter RG, Mol BW, van der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008;178:70111.
  • 18
    Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter RG, Duley L, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008;12:1286.
  • 19
    Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:17918.
  • 20
    Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev Reviews 2007 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI : 10 10 2007.
  • 21
    Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001;322:32933.
  • 22
    Coomarasamy A, Papaioannou S, Gee H, Khan KS. Aspirin for the prevention of preeclampsia in women with abnormal uterine artery Doppler: a meta-analysis. Obstet Gynecol 2001;98:8616.
  • 23
    Sox H, Stren S, Owens D, Abrams HL. Assessment of Diagnostic Technology in Health Care. Rational, Methods, Problems and Directions. Monograph of the Council on Health Care Technology. Washington: National Academy Press, 1989.
  • 24
    Bruns DE. Laboratory-related outcomes in healthcare. Clin Chem 2001;47:154752.
  • 25
    Hunink MG, Krestin GP. Study design for concurrent development, assessment, and implementation of new diagnostic imaging technology. Radiology 2002;222:60414.
  • 26
    Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med 2006;144:8505.
  • 27
    Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:20207.
  • 28
    Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1994;271:38991.
  • 29
    Cnossen JS, ter RG, Mol BW, van der Post JA, Leeflang MM, Meads CA, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand 2009;88:75865.
  • 30
    Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med 1992;116:7884.
  • 31
    Smith GD, Egger M. Going beyond the grand mean: subgroup analysis in meta-analysis of randomised trials. In: EggerM, SmithGD, AltmanDG, editors. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Books; 2001. pp. 14356.
  • 32
    Gelber RD, Goldhirsch A. Interpretation of results from subset analyses within overviews of randomized clinical trials. Stat Med 1987;6:37188.
  • 33
    Pocock SJ, Hughes MD. Estimation issues in clinical trials and overviews. Stat Med 1990;9:65771.
  • 34
    Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41:36172.
  • 35
    Shuster J, van Eys J. Interaction between prognostic factors and treatment. Control Clin Trials 1983;4:20914.
  • 36
    Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003;101:131932.